TARO PHARMACEUTICAL INDS LTD's ticker is TARO and the CUSIP is M8737E108. A total of 79 filers reported holding TARO PHARMACEUTICAL INDS LTD in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20,737,265 | -1.0% | 549,908 | -0.4% | 0.01% | 0.0% |
| Q2 2023 | $20,943,566 | +50.3% | 552,162 | -3.6% | 0.01% | +40.0% |
| Q1 2023 | $13,933,052 | +84016.5% | 572,905 | +0.4% | 0.01% | 0.0% |
| Q4 2022 | $16,564 | -99.9% | 570,370 | +0.6% | 0.01% | -28.6% |
| Q3 2022 | $17,003,000 | -15.4% | 567,195 | +2.1% | 0.01% | 0.0% |
| Q2 2022 | $20,092,000 | -13.1% | 555,613 | +3.9% | 0.01% | 0.0% |
| Q1 2022 | $23,128,000 | -10.7% | 534,629 | +3.5% | 0.01% | -12.5% |
| Q4 2021 | $25,891,000 | -22.2% | 516,682 | -1.2% | 0.01% | -27.3% |
| Q3 2021 | $33,261,000 | -11.5% | 522,713 | +0.1% | 0.01% | -8.3% |
| Q2 2021 | $37,566,000 | +1.4% | 522,040 | +3.9% | 0.01% | 0.0% |
| Q1 2021 | $37,060,000 | +5.4% | 502,493 | +4.9% | 0.01% | -7.7% |
| Q4 2020 | $35,166,000 | +35.2% | 478,994 | +1.0% | 0.01% | +18.2% |
| Q3 2020 | $26,007,000 | -15.1% | 474,162 | +2.9% | 0.01% | -15.4% |
| Q2 2020 | $30,645,000 | +11.3% | 460,887 | +2.4% | 0.01% | -7.1% |
| Q1 2020 | $27,542,000 | -21.3% | 450,003 | +13.1% | 0.01% | +7.7% |
| Q4 2019 | $34,990,000 | +19.2% | 397,924 | +2.3% | 0.01% | +18.2% |
| Q3 2019 | $29,345,000 | -2.7% | 388,923 | +10.1% | 0.01% | -8.3% |
| Q2 2019 | $30,173,000 | -11.0% | 353,223 | +12.6% | 0.01% | -14.3% |
| Q1 2019 | $33,917,000 | +33.1% | 313,808 | +4.3% | 0.01% | +16.7% |
| Q4 2018 | $25,476,000 | -3.8% | 300,981 | +11.7% | 0.01% | +20.0% |
| Q3 2018 | $26,484,000 | -11.6% | 269,426 | +4.0% | 0.01% | -16.7% |
| Q2 2018 | $29,972,000 | +16.4% | 259,071 | -0.6% | 0.01% | +9.1% |
| Q1 2018 | $25,739,000 | +2.3% | 260,672 | +8.5% | 0.01% | +10.0% |
| Q4 2017 | $25,159,000 | +0.4% | 240,265 | +8.1% | 0.01% | -9.1% |
| Q3 2017 | $25,051,000 | +25.3% | 222,310 | +24.6% | 0.01% | +22.2% |
| Q2 2017 | $19,991,000 | +30.0% | 178,392 | +35.3% | 0.01% | +28.6% |
| Q1 2017 | $15,375,000 | +23.6% | 131,822 | +11.5% | 0.01% | +16.7% |
| Q4 2016 | $12,442,000 | -1.6% | 118,197 | +3.3% | 0.01% | -14.3% |
| Q3 2016 | $12,641,000 | -17.5% | 114,367 | +8.6% | 0.01% | -22.2% |
| Q2 2016 | $15,329,000 | +6.1% | 105,286 | +4.4% | 0.01% | 0.0% |
| Q1 2016 | $14,446,000 | +1.6% | 100,854 | +9.6% | 0.01% | 0.0% |
| Q4 2015 | $14,225,000 | +8.8% | 92,040 | +0.5% | 0.01% | 0.0% |
| Q3 2015 | $13,078,000 | +20.6% | 91,540 | +21.3% | 0.01% | +28.6% |
| Q2 2015 | $10,840,000 | +77.7% | 75,442 | +74.5% | 0.01% | +75.0% |
| Q1 2015 | $6,100,000 | +16.2% | 43,244 | +22.1% | 0.00% | +33.3% |
| Q4 2014 | $5,249,000 | +34.1% | 35,418 | +39.3% | 0.00% | 0.0% |
| Q3 2014 | $3,914,000 | +19.4% | 25,431 | +8.7% | 0.00% | +50.0% |
| Q2 2014 | $3,278,000 | +58.4% | 23,385 | +25.5% | 0.00% | 0.0% |
| Q1 2014 | $2,069,000 | +373.5% | 18,638 | +321.6% | 0.00% | – |
| Q4 2013 | $437,000 | +197.3% | 4,421 | +129.2% | 0.00% | – |
| Q3 2013 | $147,000 | – | 1,929 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 545,583 | $34,715,000 | 10.89% |
| Murchinson Ltd. | 100,000 | $6,363,000 | 3.16% |
| Eversept Partners, LP | 179,366 | $11,413,059 | 0.79% |
| BRANDES INVESTMENT PARTNERS, LP | 266,560 | $16,962,000 | 0.37% |
| Analyst IMS Investment Management Services Ltd. | 22,755 | $1,447,000 | 0.18% |
| Claret Asset Management Corp | 9,336 | $594,000 | 0.10% |
| ACADIAN ASSET MANAGEMENT LLC | 344,023 | $21,851,000 | 0.08% |
| Renaissance Technologies | 720,500 | $45,845,000 | 0.06% |
| C M BIDWELL & ASSOCIATES LTD | 1,155 | $73,000 | 0.05% |
| First Trust Direct Indexing L.P. | 3,357 | $214,000 | 0.03% |